Allogene Therapeutics ALLO Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's operating lease liabilities?
- Allogene Therapeutics (ALLO) reported operating lease liabilities of $72.63M in Q1 2026.
- How has Allogene Therapeutics's operating lease liabilities changed year-over-year?
- Allogene Therapeutics's operating lease liabilities decreased by 10.7% year-over-year, from $81.29M to $72.63M.
- What is the long-term trend for Allogene Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's operating lease liabilities has grown at a 8.1% compound annual growth rate (CAGR), from $50.81M to $75.05M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.